Posted inBiotechnology
Breakthroughs and Future of Large DNA Editing
In an era marked by the critical need for sustainable agriculture and food security, the manipulation of plant genomes stands…
Posted inBiotechnology
Resolving the Muscle Ultrasound Dilemma: Future Ahead?
The future of muscle assessment in older adults has become an area of increasing interest in medical research, especially given…
Posted inBiotechnology
X Chromosome Inactivation in Humans: Implications Unveiled
The intricate workings of the human genome have always fascinated researchers, offering insights into various biological processes that dictate health…
Posted inBiotechnology
Myeloid Cells and Tregs Signal Breast Metastasis
In a significant advancement for breast cancer diagnostics, researchers have uncovered a potent predictive biomarker combination involving myeloid-derived suppressor cells…
Posted inBiotechnology
Linking Kids’ Activity to Mental Health Issues
The increasing prevalence of mental health issues among children has sparked a growing concern among researchers and health professionals alike.…
Posted inBiotechnology
Nursing Students’ Environmental Health Literacy Explored
In the modern landscape of healthcare, the significance of environmental health literacy among nursing students cannot be overstated. As future…
Posted inBiotechnology
Versant’s Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already…
Posted inBiotechnology
J&J’s $5B Alzheimer’s hope fades as anti-tau antibody posdinemab flops in phase 2
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop.…
Posted inMedical Technology
Solventum to buy Acera Surgical for up to $850M, repurchase $1B in stock
Solventum, which spun out of 3M nearly two years ago, will shell out up to $850 million for wound care…
Posted inBiotechnology
Bayer’s asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to…